AstraZeneca plc vs Global X Robo Global Robotics & Automation ETF — how do they compare? AstraZeneca plc trades at $158.4 (market cap $248.14B), while Global X Robo Global Robotics & Automation ETF trades at $84.63. The key difference: AstraZeneca plc pays a 2.01% dividend while Global X Robo Global Robotics & Automation ETF pays none, and Global X Robo Global Robotics & Automation ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | ROBO | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Sector/Thematic |
52-Week High | $209.48 | $90.34 |
52-Week Low | $147.06 | $62.34 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $158.48, down 2.12% amid bearish technical signals and merger speculation. The stock shows strong fundamentals with revenue growth from $54.1B in 2024 to $58.7B in 2025 and net income reaching $10.2B. Recent earnings beats and a 47.5% analyst buy rating contrast with technical indicators showing oversold conditions near key support at $155.
Investment outlook remains positive based on earnings momentum and valuation metrics (P/E 23.76), though risks include potential merger integration challenges and ongoing legal investigations. The company's robust cash flow generation and dividend payments provide shareholder value support despite near-term volatility.
ROBO Global Robotics and Automation Index ETF (ROBO) trades at $84.79, up 1.59% with strong bullish technical signals from moving averages. The robotics ETF benefits from AI infrastructure expansion and recent sector momentum, though key valuation metrics remain undisclosed. Recent news highlights robotics as the next phase of AI investment beyond semiconductors, with thematic ETF comparisons favoring ROBO's diversified approach to automation exposure.
Outlook remains positive given structural AI adoption tailwinds, but elevated RSI levels suggest near-term consolidation risk. The ETF's 79-stock global portfolio offers diversified robotics exposure, though cyclical industrial dependencies and valuation concerns after recent rallies present balanced risk-reward dynamics for long-term investors.
Trailing returns across standard periods
Latest headlines on both assets
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →